Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 76 for your search:
Drug:
pegylated liposomal doxorubicin hydrochloride
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase IV Randomized Study of Doxorubicin Hydrochloride Liposome Versus Capecitabine as First-Line Chemotherapy in Women With Metastatic Breast Cancer
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
SPRI-P04445
, EU-20654, NCT00266799, SPRI-PELICAN
2.
A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging
Phase:
Phase IV
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
LITE Randomized Pilot Study
, NCT00531973
3.
Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059 AM2)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
65 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
P05059
, NCT00604968
4.
A Study of Docetaxel Monotherapy or DOXIL®/CAELYX® and Docetaxel in Patients With Advanced Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
DOXIL-BCA-3001
, NCT00091442
5.
Phase III Randomized Study of Adjuvant Therapy Comprising Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With Versus Without Bevacizumab in Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-E5103
, E5103, NCT00433511
6.
Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence and to Prolong the Platinum Free Interval
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
MITO-8
, EudraCT number: 2008-001755-22, NCT00657878
7.
Phase I/II Study of Ixabepilone and Pegylated Doxorubicin HCl Lipsome in Women With Previously Treated Advanced Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer or Metastatic Breast Cancer (Phase I Closed to Accrual as of 12/6/07)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
AECM-0504007857
, NCI-7229, 7229, NCT00182767
8.
Phase I/II Study of Doxorubicin HCl Liposome, Melphalan, and Bortezomib in Patients With Relapsed or Refractory Stage I-III Multiple Myeloma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CPMC-AAAB6443
, NCT00334932
9.
TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
ONC-2005-001
, EUDRACT 2005-004569-40, NCT00289809
10.
Phase I/II Study of Pegylated Doxorubicin HCl Liposome in Combination With Oral Cyclophosphamide and Trastuzumab (Herceptin®) in Patients With Stage IV Breast Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UWCC-UW-6139
, 6139, UW CC-05-9209-H/D, FHCRC-6139, NCT00331552
11.
Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
IRB# 575-03
, NCT00456989
12.
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UMCC 2007.098
, NCT00724568
13.
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With MM
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
MCC-15399
, IRB 106692, Millennium X05248, Ortho Biotech DOXILMMY2008, NCT00750815
14.
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
0711003269
, NCT00785798
15.
Phase I/II Study of Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Multiple Myeloma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
UWCC-6817
, UWCC-6817, IR-6817, FHCRC-6817, NCT00849251
16.
Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
D4200C00083
, EUDRACT no 2008-0005557-38, NCT00862836
17.
Phase II Study of Whole Body Hyperthermia Combined With Doxorubicin HCl Liposome and Fluorouracil in Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UTHSC-MS-96205
, NCI-V97-1356, NCT00003135
18.
Phase II Randomized Study of Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Receiving Chemoembolization
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCLA-0206060
, 02-06-060, NCI-G02-2124, NCT00049322
19.
Phase II Study of Doxorubicin HCl Liposome in Patients With Stage IIB, IVA, or IVB Recurrent or Refractory Mycosis Fungoides
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
EORTC-21012
, NCT00074087, EUDRACT-2004-001746-32
20.
Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 90
Sponsor:
NCRR
Protocol IDs:
NCRR-M01RR00030-0156
, M01RR00030, NCT00006433
21.
Phase II Study of Rituximab, Cyclophosphamide, Pegylated Doxorubicin HCl Liposome, Vincristine, and Prednisone in Older Patients With Previously Untreated Aggressive Diffuse Large B-Cell Stage II-IV Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
61 and over
Sponsor:
NCI
Protocol IDs:
MDA-CCOP-2004-0305
, 2004-0305, 6485, NCI-6485, NCT00101010
22.
Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
0504007841
, NCT00148317
23.
A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
DO03-21-005
, NCT00159094
24.
Phase II Study of Cytoreductive Combination Chemotherapy Followed By Radiotherapy, High-Dose Combination Chemotherapy, and Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 72
Sponsor:
NCI
Protocol IDs:
MSKCC-04047
, NCT00255723
25.
Phase II Study of Doxorubicin HCl Liposome Followed By Bexarotene in Patients With Stage IB-IV Cutaneous T-Cell Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-05098
, NCT00255801
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
